Literature DB >> 8070496

Paroxysmal atrial fibrillation: a disorder of autonomic tone?

P Coumel1.   

Abstract

Electrophysiological characteristics of atrial cells (action potential duration and refractoriness, conduction speed) are modulated differently by vagal and sympathetic influences. The former tends to favour macro-reentry phenomena whereas the latter favours abnormal automaticity and triggered activity. In normal hearts vagal influences are predominant, thus explaining that the clinical pattern of vagal-mediated paroxysmal atrial fibrillation is preferentially observed in the absence of detectable heart disease, in young male adults, with an ECG pattern of common flutter alternating with fibrillation. Symathetically mediated atrial fibrillation is observed in the presence of any heart disease, the first effect of which is to provoke a vagal withdrawal. The clinical history is a reliable guide for suspecting which type of physiological autonomic predominance contributes to destabilize the arrhythmogenic substrate, but observing the behaviour of sinus rate variability just preceding the onset of the arrhythmia only permits documentation of the mechanism. The role of the autonomic influences should be taken into consideration every time conventional antiarrhythmic treatment is insufficient. Beta-blockers as well as digitalis may be either beneficial or detrimental, according to the causal mechanism, so that the choice of their use as a single or a combined therapy should be appropriate.

Entities:  

Mesh:

Year:  1994        PMID: 8070496     DOI: 10.1093/eurheartj/15.suppl_a.9

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  77 in total

Review 1.  Physiology and pathophysiology of the atria: its role in atrial fibrillation.

Authors:  J Godtfredsen
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

2.  Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation.

Authors:  Babar Parvez; Joseph Vaglio; Shane Rowan; Raafia Muhammad; Gayle Kucera; Tanya Stubblefield; Shannon Carter; Dan Roden; Dawood Darbar
Journal:  J Am Coll Cardiol       Date:  2012-06-20       Impact factor: 24.094

Review 3.  Lessons from computer simulations of ablation of atrial fibrillation.

Authors:  Vincent Jacquemet
Journal:  J Physiol       Date:  2016-03-04       Impact factor: 5.182

4.  Lone atrial fibrillation in vigorously exercising middle aged men: case-control study.

Authors:  J Karjalainen; U M Kujala; J Kaprio; S Sarna; M Viitasalo
Journal:  BMJ       Date:  1998-06-13

5.  Early electrocardiographic evaluation of atrial fibrillation risk in beta-thalassemia major patients.

Authors:  Vincenzo Russo; Anna Rago; Bruno Pannone; Federica Di Meo; Andrea Antonio Papa; Maria Carolina Mayer; Anna Spasiano; Maria Giovanna Russo; Paolo Golino; Raffaele Calabrò; Gerardo Nigro
Journal:  Int J Hematol       Date:  2011-03-10       Impact factor: 2.490

Review 6.  Dysfunction of the autonomic nervous system in atrial fibrillation.

Authors:  Yutao Xi; Jie Cheng
Journal:  J Thorac Dis       Date:  2015-02       Impact factor: 2.895

Review 7.  Atrial Fibrillation in Athletes - The Story Behind The Running Hearts.

Authors:  Shaolong Li; Zhihui Zhang; Benjamin J Scherlag; Sunny S Po
Journal:  J Atr Fibrillation       Date:  2010-03-01

Review 8.  Endurance Sport Practice and Atrial Fibrillation.

Authors:  Naiara Calvo; Lluis Mont
Journal:  J Atr Fibrillation       Date:  2010-10-22

9.  Running, esophageal acid reflux, and atrial fibrillation: a chain of events linked by evidence from separate medical literatures.

Authors:  Don R Swanson
Journal:  Med Hypotheses       Date:  2008-05-05       Impact factor: 1.538

10.  Increased p-wave duration and p-wave dispersion in patients with aortic stenosis.

Authors:  Hasan Turhan; Ertan Yetkin; Ramazan Atak; Tayfun Altinok; Kubilay Senen; Mehmet Ileri; Hatice Sasmaz; Sengul Cehreli; Emine Kutuk
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-01       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.